Ruch Stuart R, Nishio Manabu, Wasserstrom J Andrew
Department of Medicine, Feinberg Cardiovascular Research Institute, Northwestern University Medical School, Chicago, IL 60611, USA.
J Pharmacol Exp Ther. 2003 Oct;307(1):419-28. doi: 10.1124/jpet.103.049189. Epub 2003 Sep 3.
There is increasing evidence that cardiac glycosides act through mechanisms distinct from inhibition of the sodium pump but which may contribute to their cardiac actions. To more fully define differences between agents indicative of multiple sites of action, we studied changes in contractility and action potential (AP) configuration in cat ventricular myocytes produced by six cardiac glycosides (ouabain, ouabagenin, dihydroouabain, actodigin, digoxin, and resibufogenin). AP shortening was observed only with ouabain and actodigin. There was extensive inotropic variability between agents, with some giving full inotropic effects before automaticity occurred whereas others produced minimal inotropy before toxicity. AP shortening was not a result of alterations in calcium current or the inward rectifier potassium current, but correlated with an increase in steady-state outward current (Iss), which was sensitive to KB-R7943, a Na+-Ca2+ exchange (NCX) inhibitor. Interestingly, Iss was observed following exposure to ouabain and dihydroouabain, suggesting that an additional mechanism is operative with dihydroouabain that prevents AP shortening. Further investigation into differences in inotropy between ouabagenin, dihydroouabain and ouabain revealed almost identical responses under AP voltage clamp. Thus all agents appear to act on the sodium pump and thereby secondarily increase the outward reverse mode NCX current, but the extent of AP duration shortening and positive inotropy elicited by each agent is limited by development of their toxic actions. The quantitative differences between cardiac glycosides suggest that mechanisms independent of sodium pump inhibition may result from an altered threshold for calcium overload possibly involving direct or indirect effects on calcium release from the sarcoplasmic reticulum.
越来越多的证据表明,强心苷的作用机制不同于抑制钠泵,但其可能有助于其心脏作用。为了更全面地定义指示多个作用位点的药物之间的差异,我们研究了六种强心苷(哇巴因、哇巴因苷元、二氢哇巴因、阿克多苷、地高辛和脂蟾毒配基)对猫心室肌细胞收缩性和动作电位(AP)形态的影响。仅在哇巴因和阿克多苷作用下观察到AP缩短。各药物之间存在广泛的变力性差异,一些药物在出现自动节律之前产生完全的变力作用,而另一些药物在产生毒性之前产生最小的变力作用。AP缩短不是钙电流或内向整流钾电流改变的结果,而是与稳态外向电流(Iss)增加相关,该电流对钠钙交换体(NCX)抑制剂KB-R7943敏感。有趣的是,在暴露于哇巴因和二氢哇巴因后观察到Iss,这表明二氢哇巴因存在一种额外的机制可防止AP缩短。对哇巴因苷元、二氢哇巴因和哇巴因之间变力性差异的进一步研究表明,在AP电压钳制下它们的反应几乎相同。因此,所有药物似乎都作用于钠泵,从而继发增加外向反向模式NCX电流,但每种药物引起的AP持续时间缩短和正性变力作用的程度受到其毒性作用发展的限制。强心苷之间的定量差异表明,独立于钠泵抑制的机制可能是由于钙超载阈值改变所致,可能涉及对肌浆网钙释放的直接或间接影响。